[Combination chemotherapy for gastric cancer including LV/5-FU].

Abstract

LV (l-LV)/5-FU therapy has been used broadly and is considered to be a standard treatment for large bowel cancer due to an enhancing therapeutic effect of 5-FU. According to recent clinical study reports on large bowel cancer in Europe and the United States, various administration methods of LV/5-FU with a combination of other drugs have been devised. It appeared that 5-FU used together in bolus and continuous infusions have yielded outstanding results. Although the basis of combination therapy for gastric cancer seemed to be LV/5-FU, there were many reports on TS-1 combined with other drugs because the oral medicine TS-1 was domestically available for the past one or two years. Currently, controlled randomized trials of LV/5-FU therapy and TS-1 have been ongoing. However, when patients cannot take oral intakes, LV/5-FU therapy is important. It seems that LV/5-FU therapy in combination with other drugs, in particular, CDDP, CPT-11, paclitaxel, docetaxel, oxaliplatin, and ETP will be given as candidates for the standard treatment of gastric cancer.

• Authors: Tsuneo Sasaki, Yoshiharu Maeda, Kouji Kandaba-shi, Makiko Ono
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 31 Issue 12 Pg. 1952-6 (Nov 2004) ISSN: 0385-0684 [Print] Japan
• PMID: 15570919 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Cisplatin
• Leucovorin
• Fluorouracil

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Drug Administration Schedule
• Fluorouracil (administration & dosage)
• Humans
• Leucovorin (administration & dosage)
• Stomach Neoplasms (drug therapy, mortality)
• Survival Rate